Cambridge Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$706K Buy
13,021
+445
+4% +$20K 0.12% 101
2026
Q2
$529K Buy
12,576
+3,283
+35% +$105K 0.09% 122
2026
Q1
$246K Buy
9,293
+1,031
+12% +$30.2K 0.05% 164
2025
Q4
$239K Buy
+8,262
New +$248K 0.05% 167
2022
Q2
– Sell
-22,617
Closed -$1.04M – 178
2022
Q1
$1.04M Buy
22,617
+400
+2% +$19.1K 0.25% 65
2021
Q4
$1.36M Sell
22,217
-698
-3% -$48.3K 0.31% 57
2021
Q3
$1.71M Buy
22,915
+386
+2% +$32.4K 0.42% 35
2021
Q2
$2.08M Buy
22,529
+4,278
+23% +$364K 0.5% 30
2021
Q1
$1.62M Buy
18,251
+2,902
+19% +$288K 0.41% 40
2020
Q4
$1.43M Buy
15,349
+903
+6% +$71.9K 0.39% 43
2020
Q3
$920K Buy
14,446
+730
+5% +$42.8K 0.27% 65
2020
Q2
$715K Buy
13,716
+1,648
+14% +$70.7K 0.22% 74
2020
Q1
$377K Sell
12,068
-6,558
-35% -$219K 0.14% 95
2019
Q4
$624K Sell
18,626
-282
-1% -$8.96K 0.19% 83
2019
Q3
$558K Buy
18,908
+225
+1% +$7.31K 0.18% 78
2019
Q2
$644K Buy
18,683
+408
+2% +$13.1K 0.21% 78
2019
Q1
$601K Sell
18,275
-500
-3% -$14.8K 0.2% 81
2018
Q4
$450K Buy
18,775
+5,775
+44% +$163K 0.17% 90
2018
Q3
$435K Buy
13,000
+4,100
+46% +$130K 0.15% 91
2018
Q2
$259K Buy
8,900
+450
+5% +$12.5K 0.09% 121
2018
Q1
$218K Buy
+8,450
New +$229K 0.08% 129

Other funds holding ARKG

Cambridge Advisors's ARKG Position: Q3 2026 in Review

Cambridge Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 3.5% in Q3 2026, buying an estimated $20K and bringing the position to 13,021 shares worth $706K. The position accounts for 0.12% of the portfolio, ranked #101.

Cambridge Advisors first reported a position in ARKG in Q1 2018 and has held it in 21 quarters since. The position peaked at $2.08M in Q2 2021. 316 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • Cambridge Advisors held 13,021 shares of ARK Genomic Revolution ETF worth $706K as of Q3 2026.
  • Cambridge Advisors bought 445 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $20K.
  • ARK Genomic Revolution ETF made up 0.12% of Cambridge Advisors's portfolio in Q3 2026, its #101 holding.
  • Cambridge Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 21 quarters since.
  • Cambridge Advisors's ARK Genomic Revolution ETF position peaked at $2.08M in Q2 2021.
  • 316 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Cambridge Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.